
Insmed (INSM) Stock Forecast & Price Target
Insmed (INSM) Analyst Ratings
Bulls say
Insmed Inc is experiencing a positive outlook driven by the increased revenue estimates for its products, notably raising the 2033E POS-adjusted worldwide Brinsupri NCFB sales estimate to approximately $8.5 billion from $7.3 billion. The company is expanding its revenue forecast by including projections for Treprostinil Palmitil Inhalation Powder (TPIP) for idiopathic pulmonary fibrosis (IPF) and demonstrating heightened confidence in its long-term product pipeline. Additionally, a decrease in the terminal decline rate in discounted cash flow calculations reflects improved expectations for the sustainability of revenue streams from Insmed’s therapeutic offerings.
Bears say
Insmed Inc faces significant challenges that contribute to a negative outlook, primarily due to potential delays in enrolling and completing necessary clinical studies for its products, including ARIKAYCE, Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP). Such delays could substantially lower the probability of success estimations for these drugs, leading to detrimental effects on the company's overall valuation. Additionally, regulatory hurdles anticipated for TPIP may prevent its entry into the idiopathic pulmonary fibrosis (IPF) market until as late as 2034, further compounding the company's growth concerns and financial outlook.
This aggregate rating is based on analysts' research of Insmed and is not a guaranteed prediction by Public.com or investment advice.
Insmed (INSM) Analyst Forecast & Price Prediction
Start investing in Insmed (INSM)
Order type
Buy in
Order amount
Est. shares
0 shares